000268317 001__ 268317
000268317 005__ 20240403113236.0
000268317 0247_ $$2pmc$$apmc:PMC10881642
000268317 0247_ $$2doi$$a10.1007/s00259-023-06493-w
000268317 0247_ $$2pmid$$apmid:37971501
000268317 0247_ $$2ISSN$$a1619-7070
000268317 0247_ $$2ISSN$$a1619-7089
000268317 0247_ $$2altmetric$$aaltmetric:156504360
000268317 037__ $$aDZNE-2024-00199
000268317 041__ $$aEnglish
000268317 082__ $$a610
000268317 1001_ $$0P:(DE-2719)9002610$$aStockbauer, Anna$$b0$$eFirst author$$udzne
000268317 245__ $$aMetabolic network alterations as a supportive biomarker in dementia with Lewy bodies with preserved dopamine transmission.
000268317 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2024
000268317 3367_ $$2DRIVER$$aarticle
000268317 3367_ $$2DataCite$$aOutput Types/Journal article
000268317 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1709031182_12962
000268317 3367_ $$2BibTeX$$aARTICLE
000268317 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000268317 3367_ $$00$$2EndNote$$aJournal Article
000268317 520__ $$aMetabolic network analysis of FDG-PET utilizes an index of inter-regional correlation of resting state glucose metabolism and has been proven to provide complementary information regarding the disease process in parkinsonian syndromes. The goals of this study were (i) to evaluate pattern similarities of glucose metabolism and network connectivity in dementia with Lewy bodies (DLB) subjects with subthreshold dopaminergic loss compared to advanced disease stages and to (ii) investigate metabolic network alterations of FDG-PET for discrimination of patients with early DLB from other neurodegenerative disorders (Alzheimer's disease, Parkinson's disease, multiple system atrophy) at individual patient level via principal component analysis (PCA).FDG-PETs of subjects with probable or possible DLB (n = 22) without significant dopamine deficiency (z-score < 2 in putamen binding loss on DaT-SPECT compared to healthy controls (HC)) were scaled by global-mean, prior to volume-of-interest-based analyses of relative glucose metabolism. Single region metabolic changes and network connectivity changes were compared against HC (n = 23) and against DLB subjects with significant dopamine deficiency (n = 86). PCA was applied to test discrimination of patients with DLB from disease controls (n = 101) at individual patient level.Similar patterns of hypo- (parietal- and occipital cortex) and hypermetabolism (basal ganglia, limbic system, motor cortices) were observed in DLB patients with and without significant dopamine deficiency when compared to HC. Metabolic connectivity alterations correlated between DLB patients with and without significant dopamine deficiency (R2 = 0.597, p < 0.01). A PCA trained by DLB patients with dopamine deficiency and HC discriminated DLB patients without significant dopaminergic loss from other neurodegenerative parkinsonian disorders at individual patient level (area-under-the-curve (AUC): 0.912).Disease-specific patterns of altered glucose metabolism and altered metabolic networks are present in DLB subjects without significant dopaminergic loss. Metabolic network alterations in FDG-PET can act as a supporting biomarker in the subgroup of DLB patients without significant dopaminergic loss at symptoms onset.
000268317 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000268317 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000268317 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000268317 650_7 $$2Other$$aDaT-Scan
000268317 650_7 $$2Other$$aDementia with Lewy bodies
000268317 650_7 $$2Other$$aFDG-PET
000268317 650_7 $$2Other$$aMetabolic connectivity
000268317 650_7 $$0VTD58H1Z2X$$2NLM Chemicals$$aDopamine
000268317 650_7 $$00Z5B2CJX4D$$2NLM Chemicals$$aFluorodeoxyglucose F18
000268317 650_7 $$0IY9XDZ35W2$$2NLM Chemicals$$aGlucose
000268317 650_2 $$2MeSH$$aHumans
000268317 650_2 $$2MeSH$$aLewy Body Disease: diagnostic imaging
000268317 650_2 $$2MeSH$$aDopamine: metabolism
000268317 650_2 $$2MeSH$$aFluorodeoxyglucose F18
000268317 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000268317 650_2 $$2MeSH$$aPositron-Emission Tomography
000268317 650_2 $$2MeSH$$aGlucose: metabolism
000268317 650_2 $$2MeSH$$aMetabolic Networks and Pathways
000268317 7001_ $$aBeyer, Leonie$$b1
000268317 7001_ $$aHuber, Maria$$b2
000268317 7001_ $$aKreuzer, Annika$$b3
000268317 7001_ $$0P:(DE-2719)9000852$$aPalleis, Carla$$b4$$udzne
000268317 7001_ $$0P:(DE-2719)9001160$$aKatzdobler, Sabrina$$b5
000268317 7001_ $$0P:(DE-2719)9001808$$aRauchmann, Boris Stephan$$b6$$udzne
000268317 7001_ $$aMorbelli, Silvia$$b7
000268317 7001_ $$aChincarini, Andrea$$b8
000268317 7001_ $$aBruffaerts, Rose$$b9
000268317 7001_ $$aVandenberghe, Rik$$b10
000268317 7001_ $$aKramberger, Milica G$$b11
000268317 7001_ $$aTrost, Maja$$b12
000268317 7001_ $$aGaribotto, Valentina$$b13
000268317 7001_ $$aNicastro, Nicolas$$b14
000268317 7001_ $$aLathuilière, Aurélien$$b15
000268317 7001_ $$aLemstra, Afina W$$b16
000268317 7001_ $$avan Berckel, Bart N M$$b17
000268317 7001_ $$aPilotto, Andrea$$b18
000268317 7001_ $$aPadovani, Alessandro$$b19
000268317 7001_ $$aOchoa-Figueroa, Miguel A$$b20
000268317 7001_ $$aDavidsson, Anette$$b21
000268317 7001_ $$aCamacho, Valle$$b22
000268317 7001_ $$aPeira, Enrico$$b23
000268317 7001_ $$aBauckneht, Matteo$$b24
000268317 7001_ $$aPardini, Matteo$$b25
000268317 7001_ $$aSambuceti, Gianmario$$b26
000268317 7001_ $$aAarsland, Dag$$b27
000268317 7001_ $$aNobili, Flavio$$b28
000268317 7001_ $$aGross, Mattes$$b29
000268317 7001_ $$0P:(DE-2719)2811820$$aVöglein, Jonathan$$b30$$udzne
000268317 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b31$$udzne
000268317 7001_ $$aPogarell, Oliver$$b32
000268317 7001_ $$0P:(DE-2719)2811351$$aBuerger, Katharina$$b33$$udzne
000268317 7001_ $$0P:(DE-2719)2811119$$aFranzmeier, Nikolai$$b34
000268317 7001_ $$0P:(DE-2719)2810712$$aDanek, Adrian$$b35$$udzne
000268317 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b36$$udzne
000268317 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b37$$udzne
000268317 7001_ $$aBartenstein, Peter$$b38
000268317 7001_ $$aCumming, Paul$$b39
000268317 7001_ $$aRominger, Axel$$b40
000268317 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b41$$eLast author
000268317 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-023-06493-w$$gVol. 51, no. 4, p. 1023 - 1034$$n4$$p1023 - 1034$$tEuropean journal of nuclear medicine and molecular imaging$$v51$$x1619-7070$$y2024
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP1.docx
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP2.docx
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP3.xlsx
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199.pdf$$yOpenAccess
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP1.doc
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP1.odt
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP1.pdf
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP2.doc
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP2.odt
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP2.pdf
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP3.csv
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP3.ods
000268317 8564_ $$uhttps://pub.dzne.de/record/268317/files/DZNE-2024-00199%20SUP3.xls
000268317 909CO $$ooai:pub.dzne.de:268317$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000268317 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002610$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000268317 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000852$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000268317 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001160$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000268317 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001808$$aExternal Institute$$b6$$kExtern
000268317 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811820$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b30$$kDZNE
000268317 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b31$$kDZNE
000268317 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811351$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b33$$kDZNE
000268317 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811119$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b34$$kDZNE
000268317 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810712$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b35$$kDZNE
000268317 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b36$$kDZNE
000268317 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b37$$kDZNE
000268317 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b41$$kDZNE
000268317 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000268317 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000268317 9141_ $$y2024
000268317 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000268317 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-23
000268317 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-23
000268317 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000268317 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-23
000268317 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2023-08-23
000268317 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-23
000268317 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-23$$wger
000268317 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000268317 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000268317 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-23
000268317 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2023-08-23
000268317 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000268317 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-23
000268317 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000268317 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000268317 9201_ $$0I:(DE-2719)1110008$$kAG Simons$$lMolecular Neurobiology$$x1
000268317 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x2
000268317 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x3
000268317 980__ $$ajournal
000268317 980__ $$aVDB
000268317 980__ $$aUNRESTRICTED
000268317 980__ $$aI:(DE-2719)1110007
000268317 980__ $$aI:(DE-2719)1110008
000268317 980__ $$aI:(DE-2719)1111015
000268317 980__ $$aI:(DE-2719)5000022
000268317 9801_ $$aFullTexts